Mucopolysaccharidosis type i

Pediatric Endocrinology Reviews

Volumn 12, Issue , 2014, Pages 102-106

  Wraith, J E ^a   Jones, Simon ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

Dermatan sulfate (DS); Enzyme Replacement Therapy (ERT); Glycosaminoglycans (GAGs); Haematopoietic Stem Cell Transplant (HSCT); Heparan sulfate (HS); Hurler; Scheie

Indexed keywords

GLYCOSAMINOGLYCAN; HEPARAN SULFATE; LARONIDASE; LEVO IDURONIDASE;

ARTICLE; CERVICAL SPINAL CORD INJURY; CLINICAL FEATURE; DYSOSTOSIS; ENZYME ASSAY; ENZYME REPLACEMENT; GENETIC DISORDER; GENOTYPE PHENOTYPE CORRELATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HIGH RISK PATIENT; HUMAN; HURLER SYNDROME; HYPOPLASIA; MONOTHERAPY; MUCOPOLYSACCHARIDOSIS; NONSENSE MUTATION; ODONTOID PROCESS; SCHEIE SYNDROME; MULTIMODALITY CANCER THERAPY; REVIEW; TREATMENT OUTCOME;

COMBINED MODALITY THERAPY; ENZYME REPLACEMENT THERAPY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IDURONIDASE; MUCOPOLYSACCHARIDOSIS I; TREATMENT OUTCOME;

EID: 84908225628     PISSN: 15654753     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Moore, D; Connock, M, J; Wraith, E; Lavery, C, The prevalence of and survival in Mucopolysaccharidosis I: Hurler, Hurler-Scheie and Scheie syndromes in the UK, Orphanet Journal of Rare Diseases (2008) 3: 24
2. Terlato NJ, Cox GF. Can mucopolysaccharidosis type I disease severity be predicted based on a patient's genotype? A comprehensive review of the literature. Genet Med. (2003) 5:286-294
3. Lachman, R; Martin, K, W; Castro, S; Basto, MA; Adams, A; Teles, E, L, Radiologic and neuroradiologic findings in the mucopolysaccharidoses, Journal of Paediatric Rehabilitation Medicine: An Interdisciplinary Approach (2010)3:109-118
4. Mundada, V; D'Souza, N, Lumbar gibbus: early presentation of dysostosis multiplex, Arch Dis Child (2009) 94: 930-931
5. Walker, R, W; Darowski, M; Morris, P; Wraith, J, E, Anaesthesia and mucopolysaccharidises. A review of airway problems in children, Anaesthesia (1994) 49:1078-1084
6. Donalsdon, M, D; Pennock, C, A; Berry, P, J; Duncan, A, W; Cawdery J, E; Leonard, J, V, Hurler syndrome with cardiomyopathy in infancy, J Pediatr (1989) 114: 430-432
7. Brosius F, C, 3rd; Roberts, W, C, Coronary artery disease in the Hurler syndrome. Qualitative and quantitative analysis of the extent of coronary narrowing at necropsy in six children, Am J Cardiol. (1981) 47: 649-653
8. Dangel, J, H, Cardiovascular changes in children with mucopolysaccharide storage diseases and related disorders-clinical and echocardiography findings in 64 patients, Eur J Paediatr (1998) 157: 534-538
9. Vijay, S; Wraith, J, E, Clinical presentation and follow-up of patients with the attenuated phenotype of mucopolysaccharidosis type I, Acta Paediatrica (2005) 94: 872-877
10. Thomas, J, A, Beck, M, Clarke, J, T, R; Cox, G, F, Childhood onset of Scheie syndrome, the attenuated form of mucopolysaccharidosis type I, J Inherit Metab Dis (2010) 33: 421-427
11. Am, P; Wraith, J, E; Underhill, L, Characterization of surgical procedures in patients with mucopolysaccharidosis type I: Findings from the MPS I registry, J Pediatr (2009) 154: 859-864
12. Cimaz, R; Vijay, S; Haase, C; Coppa, G, V; Bruni, S; Wraith, E; Guffon, N, Attenuated type I mucopolysaccharidosis in the differential diagnosis of juvenile idiopathic arthritis: a series of 13 patients with Scheie syndrome, Clin Exp Rheumatol 24:196-202
13. Tolar, J; Grewal, S, S; Bjoraker, K, J; Whitley, C, B; Shapiro, E, G; Charnas, L; Orchard, P, J, Combination of enzyme replacement and hematopoietic stem cell transplantation as therapy for Hurler syndrome, Bone Marrow Transplant (2008) 41: 531-535
14. Boelins J, J; Rocha, V; Aldenhoven, M; Wynn, R, F; O'Meara, A; Michel, G; lonescu, I; Parikh, S; Prasaad, V, K; Szaboics, P; Escolar, M; Gluckman, E; Cavazzana-Calvo, M; Kurtzberg, J; EUROCORD, Inborn error Working Party of EBMT and Duke University, Risk factor analysis of outcomes after unrelated cord blood transplantation in patients with hurler syndrome, Biol Blood Marrow Transplant (2009) 15: 618-625
15. Prasad, V, K; Kurtzberg, J, Transplant outcomes in mucopolysaccharidoses, Semin Hematol (2010) 47: 59-69
16. Aldenhoven, M; Boelens, J, J; de Konig, T, J, The clinical outcome of Hurler syndrome after stem cell transplantation, Biol Blood Marrow Transplant (2008) 14: 485-498
17. Wraith, J, E; Beck, M; Lane, R; van der Ploeg, A; Shapiro, E; Xue, Y; Kakkis, E, D; Guffon, N, Enzyme replacement therapy in patients who have mucpolysaccharidosis I and are younger than 5 years: results of a multinational study of recombinant human a-L-lduronidase (Laronidase), Pediatrics (2007) 120: e37-46
18. Wraith, J, E; Clarke, L, A; Beck, M; Kolodny, E, H; Pastores, G, M; Muenzer, J; Rapoport, D, M; Berger, K, I; Sweidler, S, J; Kakkis, E, D; Braakman, T; Chadbourne, E; Walton-Brown, K; Cox, G, F, Enzyme replacement therapy for mucopolysaccharidosis I; A randomized, double-blinded, placebo-controlled, multinational study of recombinant human a-L-lduronidase (Laronidase), J Pediatr (2004) 144; 581-588
19. Sifuentes, M; Doroshow, R; Hoft, R; Mason, G; Walot, I; Diament, M; Okazaki, S; Huff, K; Cox, G, F; Swiedler, S, J; Kakkis, E, D, A follow up study of MPS I patients treated with laronidase enzyme replacement therapy for 6 years, Molecular Genetics and Metabolism (2007) 90: 171-180
20. Clarke, L, A; Wraith, J, E; Beck, M; Kolodny, E, H; Pastores, G, M; Muenzer, J; Rapoport, D, M; Berger, K, I; Sidman, M; Kakkis, E, D; Cox, G, F, Long-term efficacy and safety of laronidase in the treatment of mucpolysaccharidosis I, Pedatrics (2009) 123: 229-240
21. Cox-Brinkman, J; Timmermans, R, G; Wijburg, F, A; Donker, W, E; van de Ploeg, A. T; Aerts, J, M; Hollak, C, E, Home treatment with enzyme replacement therapy for mucopolysaccaridosis type I is feasible and safe, J Inher Metab Dis (2007) 30: 984
22. Munoz-Rojas, M, V, Vieira, T; Costa, R; Fagondes, S; John, A; Jardim, L, B; Vedolin, L, M; Raymundo, M; Dickson, P, I; Kakkis, E; Giugliani, R, Intrathecal enzymereplacemnt therapy in a patient with mucopolysaccharidosis type I and symptomatic spinal cord compression, Am J Med Genet A (2008) 146A: 2538-2544
23. Connock M, Juarez-Garcia A, Frew E, Mans A, Dretzke J, Fry-Smith A, et al. A systematic review of the clinical effectiveness and cost-effectiveness of enzyme replacement therapies for Fabry's disease and mucopolysaccharidosis type 1. Health Technol Assess (2006) 10: (20)
24. da Silva FH, Pereira VG, Yasumura EG, Tenorio LZ, de Carvalho LP, Lisboa BC, Matsumoto PK, Stilhano RS, Samoto VY, Calegare BF, Brandao LD, D Almeida V, Filippo TR, Porcionatto M, Toma L, Nader HB, Vastos VB, Camassola M, Nardi NB, Han SW. Treatment of adult MPSI mouse brains with IDUA-expressing mesenchymal stem cells decreases GAG deposition and improves exploratory behavior. Genet Vaccines Ther. (2012) 20;10(1):2
25. Gardner, Robinson N, Meadows T, Wynn R, Will A, Mercer J, Church H, Tylee, K, Wraith JE, Clayton P. Growth, final height and endocrine sequelae in a UK population of patients with Hurler syndrome (MPS1H) Journal of Inherited Metabolic Disease. (2011), 34: 2, 489
26. Saif MA, Bigger BW, Brookes KE, Mercer J, Tylee K, Church HJ, Bonney DK, Jones S, Wraith JE, and Wynn RF. Hematopoietic stem cell transplantation ameliorates the high incidence of neutralizing allo-antibodies observed in MPSI-Hurler after pharmacological enzyme replacement therapy. Haematologica. (2012), 97